Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations

Anesthesia and Analgesia

Volumn 111, Issue 4, 2010, Pages 856-861

  Garvin, Sean ^a   Fitzgerald, Daniel ^a   Muehlschlegel, Jochen D ^a   Perry, Tjörvi E ^a   Fox, Amanda A ^a   Shernan, Stanton K ^a   Collard, Charles D ^b   Aranki, Sary ^a   Body, Simon C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; TROPONIN I; ANTITHROMBIN III;

ADULT; AGED; ANESTHESIA INDUCTION; ANTITHROMBIN ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; COLORIMETRY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; FEMALE; GENERAL ANESTHESIA; HEART MUSCLE INJURY; HEPARIN RESISTANCE; HEPARIN SENSITIVITY INDEX; HUMAN; HYPOTHESIS; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; BLOOD CLOTTING TIME; COMPARATIVE STUDY; ECONOMICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PREOPERATIVE CARE; REVIEW;

AGED; ANTITHROMBIN III; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; WHOLE BLOOD COAGULATION TIME;

EID: 77957696164     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181ce1ffa     Document Type: Article

References (29)

1. McLean J. The thromboplastin action of cephalin. Am J Physiol 1916;41:250-257
2. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-6505
3. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;292:146-151
4. Langdown J, Johnson DJ, Baglin TP, Huntington JA. Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem 2004;279:47288-47297
5. Avidan MS, Levy JH, Scholz J, Delphin E, Rosseel PM, Howie MB, Gratz I, Bush CR, Skubas N, Aldea GS, Licina M, Bonfiglio LJ, Kajdasz DK, Ott E, Despotis GJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-284
6. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-113
7. Ranucci M, Isgro G, Cazzaniga A, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002;17:199-204
8. Williams MR, D'Ambra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-877
9. Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999;14:437-442
10. Staples M, Dunton D, Karlson K, Leonardi H, Berger R. Heparin resistance after preoperative heparin therapy or intraaortic ballon pumping. Ann Thorac Surg 1994;57:1211-1216
11. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001;92:66-71
12. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33:355-360
13. Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-217
14. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506
15. Medtronic Perfusion Systems. Hepcon HMS Plus Operator s Manual. Minneapolis, MN: Medtronic Perfusion Systems, 2001
16. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956;5:328-345
17. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505-514
18. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007;67:1429-1440
19. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002;96:1095-1102
20. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-684
21. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799-804; discussion 804-805
22. Wu HF, Lundblad RL, Church FC. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995;85:421-428
23. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873
24. Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB. Regulation of thrombin generation by TFPI in plasma without and with heparin. Transl Res 2009;153:124-131
25. Barzu T, van Rijn JL, Petitou M, Tobelem G, Caen JP. Heparin degradation in the endothelial cells. Thromb Res 1987;47:601-609
26. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986;261:3980-3986
27. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995;81:35-37
28. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-240
29. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-1082